removed from the system after the second round. CVI >¼ 0.75 was achieved in 8 (11%) statements in the first round, 44 (61%) statements in the second, 17 (24%) statements in the third and 3 (4%) statements in the 4th round. The final 8 domains included: Pelvic Lymph Node Dissection, Development of the Peri-ureteral Space, Lateral Pelvic Space, Anterior Rectal Space, Control of the Vascular Pedicle, Anterior Vesical Space, Control of the Dorsal Venous Complex, and Apical Dissection (Fig 1) .
INTRODUCTION AND OBJECTIVES: Neoadjuvant chemotherapy in pure urothelial bladder cancer provides a significant survival benefit. However, it is unknown if this benefit persists in histological variants of bladder cancer. We aimed to assess the effect of neoadjuvant chemotherapy on overall survival (OS) and upstaging at radical cystectomy in the five most common histological variants.
METHODS: Querying the National Cancer Data Base, we identified 1,555 patients with histological variants undergoing radical cystectomy for muscle-invasive bladder cancer between [2003] [2004] [2005] [2006] [2007] [2008] [2009] [2010] [2011] . Neoadjuvant chemotherapy was defined as multiagent systemic therapy administered within 180 days prior to surgery. Histological variants were categorized as pure neuroendocrine tumors, squamous cell carcinoma, and adenocarcinoma, or micropapillary and sarcomatoid differentiation. Cox regression models were used to examine the effect of neoadjuvant chemotherapy on overall mortality in each variant subgroup. Logistic regression models estimated the odds of pathological upstaging at radical cystectomy for each histological variant, stratified by the receipt of neoadjuvant chemotherapy.
RESULTS CONCLUSIONS: Patients with neuroendocrine tumors benefit from neoadjuvant chemotherapy, as evidenced by better OS and lower rates of pathological upstaging at radical cystectomy. In micropapillary and sarcomatoid differentiated tumors, neoadjuvant chemotherapy decreased pathological upstaging at cystectomy. However, this favorable effect did not translate into a statistically significant OS benefit for these patients, potentially due to the aggressive tumor biology. 
INTRODUCTION AND OBJECTIVES:
Autophagy is an evolutionarily conserved mechanism that is critical for cellular homeostasis but its involvement in cancer in general has been controversial. Even less is known about the relationship between autophagy and bladder cancer development and progression. Here we explore the role of ATG7, a key autophagy-related regulator, in bladder cancer cell invasion.
METHODS: Expression of ATG7 protein in human bladder cancer specimens, cell lines and N-butyl-N-(4-hydroxybutyl)nitrosamine (BBN)-induced mouse invasive bladder cancer specimens were assessed using immunohistochemistry and immunoblotting. After ruling out transcriptional regulation, the possibility of microRNA in ATG7 expression was tested by bioinformatics search for putative miRNAs that could target 3'-UTR of ATG7 mRNA, by assessing the expression of candidate miRNAs in bladder cancer tissues and cell lines and by studying the effects of miRNAs on ATG7 expression with stable transfection. The effects of ATG7 expression on invasion was evaluated after shRNA knockdown. The levels of cell invasion effectors (RhoGDIa, RhoGDIb, Rac1, 2, 3, and RhoA) were also determined. The upstream regulators of RhoGDIb were determined using RNA-IP and verified in xenografted tumors.
RESULTS: ATG7 was markedly and reproducibly upregulated in human muscle-invasive bladder cancers, their cell-line derivatives and mouse invasive bladder cancer induced by BBN. Knockdown of ATG7 in human bladder cancer cell lines UMUC3 and T24 dramatically reduced their invasion. Mechanistic analyses showed that ATG7 overexpression was mediated by miR-190, which was also highly upregulated in bladder cancer tissues and cell lines. miR-190 bound to the 3'-UTR of ATG7 mRNA increasing its stability. A separate mechanism was that ATG7-mediated autophagic response could remove AUF1 protein and reduce AUF1 interaction with RhoGDIb mRNA, leading to Vol. 197, No. 4S, Supplement, Saturday, May 13, 2017 THE JOURNAL OF UROLOGY â e431 increased RhoGDIb mRNA stability which then promotes invasion. Indeed, inhibition of ATG7-mediated autophagy led to AUF1 protein accumulation, RhoGDIb downregulation and decreased cell invasion. CONCLUSIONS: Our results provide the first mechanistic link between autophagy and bladder cancer cell invasion. The signaling axis along ATG7-AUF1-RhoGDI' that is highly operative in bladder cancer cells might be explored further for developing novel diagnostic and therapeutic approaches to manage advanced bladder cancers.
INTRODUCTION AND OBJECTIVES: Despite cisplatin-based chemotherapy (CT) is recommended in MIUBC, an unmet need is to identify new drugs or combinations to improve the outcomes. SGC combination was evaluated in an open-label, single-arm, phase 2 trial (NCT01222676).
METHODS: After TURB, pts with T2-T4a N0 MIUBC received 4 cycles of cisplatin 70 mg/m2 d1, gemcitabine 1000 mg/m2 d1 and 8, q3 wks. Sorafenib 400 mg q12h was administered daily from day 1 until radical cystectomy. In a Simon 0 s 2-stage design, the primary endpoint was pathologic complete responses (pT0). Residual carcinoma in situ was considered pT0. ITT analysis was applied. Statistical hypothesis assumed H0: 0.20 and H1: 0.40 (a and b of 5% and 10%). ERCC1 immunohistochemistry (IHC) and next-generation sequencing (NGS) of TURB tissue, and measurement of baseline circulating VEGF levels, were planned. RESULTS: From 04/2011-06/2016, 45 pts were enrolled. 28 pts (62.2%) had macroscopical residual disease after TURB, 17 (37.8%) presented with clinical stage T3-4. pT0 was obtained in 19 pts (42.2%, 95%CI: 27.6-57.9); pT1 in 24 (53.3%, 95%CI: 37.9-68.3). After median follow-up of 35 months, median PFS was not reached (IQR: 29.4-NE), like median OS (IQR: 30.3-NE). Pathological response (pT0 vs pT1 vs other) predicted for both PFS (p¼0.015) and OS (p¼0.046). Hematologic (hem) G3-4 adverse events (AE): platelet 28.9%, neutrophils 15.6%, Hb (4.4%). Extra-hem AEs were seen in 9 pts (20%). 24 (53.3%) pts needed S temporary interruption (5 cases discontinuation).Tumor samples were available from 23 pts for ERCC1-IHC, 24 for NGS: ERCC1 IHC expression was associated with non response (pT2, p¼0.033). ERBB2/ERBB3 mutations were found only in responders (pT1, 20%). PIK3CA/AKT mutations (missense, and newly-identified mutations) were more frequent in pT2 pts (35.7% vs 20%). Baseline VEGF levels did not predict for PFS/OS. NGS of the remaining pts of the trial is ongoing.
CONCLUSIONS: SGC combination was active and effective in MIUBC. Translational analyses are providing information to develop combination of CT with new more potent and selective TKIs, possibly in more selected pts. (MIBC) is recognized as the standard of care, the management of patients with locally advanced and/or nodal disease after NAC and radical cystectomy (RC) is not well defined. We sought to evaluate the association of adjuvant chemotherapy (AC) and overall survival (OS) among patients with adverse pathology after NAC and RC.
METHODS: The National Cancer Database was reviewed to identify patients with adverse pathology (pT3N0, pT4N0, or pTanyN1-3) at RC following NAC from 2006-2012. Patients were stratified by receipt of AC. Clinical and pathologic variables were abstracted. OS was the primary end-point and differences on the basis of AC receipt among all patients and as stratified by pathologic stage were assessed by the Kaplan-Meier method and log-rank test. Multivariable Cox proportional hazards regression was used to assess the association of AC with OS controlling for age, sex, race, Charlson score, year of diagnosis, pathologic stage, and receipt of adjuvant radiotherapy.
RESULTS: Adverse pathology following NAC and RC was identified in 1,361 patients from 2006-2012, of whom 328 (24.1%) received AC. Staging was pT3N0 in 444 (32.6%), pT4N0 in 162 (11.9%), and pTanyN1-3 in 755 (55.5%). Median OS for the entire cohort was 22.9 months, which differed by pathologic stage: 34.6 months (pT3N0), 21.4 months (pT4N0), and 19.3 months (pTanyN1-3) (p<0.01). No difference in OS was noted by receipt of AC in the overall cohort (median OS 24.6 months with AC vs 22.0 months without AC; p¼0.18), or when stratified by pathologic stage. On multivariable analysis, receipt of AC was not significantly associated with overall mortality (HR 0.86; 95%CI 0.74-1.01; p¼0.06) for all patients. When stratified by stage, AC was associated with a significantly decreased risk of mortality among patients with pT4N0 disease (HR 0.56; 95%CI 0.33-0.97; p¼0.04), but not pT3N0 or pTanyN1-3 (p>0.05).
CONCLUSIONS: Patients with adverse pathology at RC after NAC have a median OS of approximately 2 years. AC was not associated with improved survival, except in the subgroup with pT4N0 disease. Clinical trials with newer systemic therapies are warranted for patients in this setting. 
